Back to search

Article

Gene expression before and after neoadjuvant chemotherapy or endocrine therapy and survival outcomes in hormone receptor-positive, HER2-negative breast cancer: the NEOENDO study

2024-02-09

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> Neoadjuvant chemotherapy (NACT) and endocrine therapy (NET) are sometimes used to shrink hormone receptor-positive (HoR+)/HER2-negative breast cancer (BC) before surgery. These treatments can change the tumor on a molecular level, but the impact on patient outcomes remains unclear. There is also a lack of detailed comparison between the changes induced by both th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e288296e-ebb6-5abd-8b53-47fb8cb923da
DOI
10.21203/rs.3.rs-3937385/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Gene expression before and after neoadjuvant chemotherapy or endocrine therapy and survival outcomes in hormone receptor-positive, HER2-negative breast cancer: the NEOENDO studyDOI 10.21203/rs.3.rs-3937385/v1
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity
Molecular characterization of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour responseSemantic proximity
A novel gene signature to predict response to neoadjuvant chemotherapy and endocrine treatment in estrogen receptor-positive breast cancer patientsSemantic proximity
Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH-positive early- stage breast cancer: A retrospective multicenter cohort studySemantic proximity
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)Semantic proximity
Integrative analysis of pre-treatment RNA expression signatures and recurrent genomic alterations: Link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancerSemantic proximity
Neoadjuvant Chemotherapy in early-stage breast cancer: the trend over time and the impact on axillary management, A National Cancer Database AnalysisSemantic proximity
Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysisSemantic proximity
Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerSemantic proximity
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancerSemantic proximity
A novel twelve-gene signature to evaluate neoadjuvant chemotherapy response and predict prognosis in breast cancerSemantic proximity
Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual DiseaseSemantic proximity
Select a neighboring publication to make it the new centre.